A PT-141 bremelanotide injection 20mg vial is a research peptide format. Learn how it compares to nasal spray, typical dosing math, duration, and safety.
A PT-141 bremelanotide injection 20mg vial is a lyophilized powder containing 20 milligrams of bremelanotide, sold for laboratory research rather than human use. The FDA-approved version of bremelanotide is Vyleesi, a 1.75 mg autoinjector pen approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. A 20 mg vial is a bulk research format that requires reconstitution and is not dosed like the commercial product.
What Is a PT-141 Bremelanotide Injection 20mg Vial?
Bremelanotide is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It works as a melanocortin receptor agonist, which researchers study for its effects on sexual desire and central nervous system pathways.
A 20 mg vial typically arrives as a sterile, lyophilized powder. Researchers reconstitute it with bacteriostatic water or sterile water before use. The 20 mg size is much larger than the 1.75 mg dose in the commercial autoinjector, so a single vial contains multiple research aliquots.
PT-141 bremelanotide injection 20mg vials are not FDA-approved for human use in that form. The FDA has only approved bremelanotide as Vyleesi 1.75 mg for HSDD in premenopausal women. That approval does not extend to bulk research vials, compounded products, or nasal sprays.
Many laboratory suppliers sell this format under the label research use only. Researchers often compare it with pt 141 injection pens and other delivery methods when designing protocols.
PT-141 Nasal Spray vs Injection: Key Differences
Researchers often compare a pt-141 nasal spray vs injection because the two routes differ in absorption, convenience, and research dosing. Nasal formulations are not FDA-approved, and absorption through the nasal mucosa can vary widely between users.
| Feature | PT-141 Nasal Spray | PT-141 Injection |
|---|---|---|
| Route | Intranasal | Subcutaneous |
| Typical research amount | 300 mcg to 2 mg per spray | 1 mg to 2 mg per injection |
| Onset | Often 30 to 60 minutes | Often 30 to 60 minutes |
| Duration | Varies; often 2 to 6 hours | Varies; often 4 to 6 hours |
| FDA status | Not approved | Vyleesi 1.75 mg approved; 20 mg vial not approved |
A pt-141 nasal spray is popular in research settings because it avoids needles. However, a pt-141 300 mcg spray 20mg product may deliver inconsistent amounts depending on spray technique and device quality.
Injection offers more precise dosing because the researcher controls the volume drawn into a syringe. That precision is a major reason the 20 mg vial format is used in laboratory work rather than clinical care.
Understanding PT-141 Injection Dosage and 20mg Vial Math
One commonly referenced pt-141 injection dosage in research is 1 mg to 2 mg given subcutaneously. The FDA-approved Vyleesi dose is 1.75 mg, injected into the abdomen or thigh at least 45 minutes before anticipated sexual activity. No more than one dose is recommended in 24 hours, and no more than eight doses per month.
A 20 mg vial contains roughly 11 doses of 1.75 mg. That math matters for reconstitution. If a researcher adds 2 mL of bacteriostatic water to a 20 mg vial, the concentration is 10 mg/mL. A 0.1 mL draw equals 1 mg, and a 0.175 mL draw equals 1.75 mg.
| Water Added | Concentration | Volume for 1 mg | Volume for 1.75 mg |
|---|---|---|---|
| 1 mL | 20 mg/mL | 0.05 mL | 0.0875 mL |
| 2 mL | 10 mg/mL | 0.1 mL | 0.175 mL |
| 4 mL | 5 mg/mL | 0.2 mL | 0.35 mL |
These numbers are for research and educational reference only. They are not a prescription, and self-dosing with a research peptide carries unknown risks.
How Long Does PT-141 Last?
Many people ask how long does pt-141 last because timing affects study design and expectations. Bremelanotide has a reported half-life of about 2.7 hours after subcutaneous injection. Effects on sexual desire are typically reported within 1 to 2 hours and can last up to 6 hours.
The duration depends on dose, route, individual metabolism, and formulation. Nasal spray effects may fade faster or slower than injection effects. A 20 mg vial does not change the half-life; it only changes the total amount of peptide available.
Some research suggests that repeated daily use can lead to reduced response, possibly through receptor desensitization. This is one reason clinical labeling limits dosing frequency.
Safety, Legal Status, and Where to Buy PT-141
Bremelanotide can raise blood pressure and temporarily reduce heart rate. Common side effects include nausea, flushing, headache, vomiting, and injection site reactions. People with uncontrolled hypertension or cardiovascular disease should not use it without medical supervision.
The legal status of a 20 mg vial differs from the prescription product. Vyleesi requires a prescription and is dispensed as a single-dose autoinjector. Research vials labeled not for human use may be sold online, but their purity, sterility, and identity are not guaranteed by the FDA.
When people search for where to buy pt-141, they often find research chemical suppliers, compounding pharmacies, and gray-market vendors. A prescription from a licensed healthcare professional remains the only lawful route for human use in the United States.
Anyone considering bremelanotide for a medical condition should consult a healthcare professional. A clinician can review cardiovascular history, medications, and contraindications before recommending any treatment.
Practical Research Handling Tips
If a 20 mg vial is used in a laboratory setting, standard pt 141 injection instructions include the following steps:
- Reconstitute the lyophilized powder with the appropriate volume of bacteriostatic water.
- Swirl gently; do not shake, because shaking can damage the peptide.
- Store the reconstituted vial in the refrigerator, typically at 2°C to 8°C.
- Use sterile syringes and alcohol swabs for every draw.
- Label the vial with the concentration and date of reconstitution.
- Dispose of needles in a sharps container.
These practices reduce contamination risk but do not make a research peptide safe for human consumption. Researchers should follow institutional biosafety guidelines and local regulations.
Key Takeaways
- A PT-141 bremelanotide injection 20mg vial is a bulk research format, not an FDA-approved drug product.
- The FDA-approved bremelanotide product is Vyleesi 1.75 mg for HSDD in premenopausal women.
- Injection offers more precise dosing than nasal spray, but both carry risks and are not approved in these research formats.
- Bremelanotide has a half-life of about 2.7 hours, and effects typically last up to 6 hours.
- Consult a healthcare professional before using bremelanotide for any medical purpose.
Frequently Asked Questions
Is a PT-141 bremelanotide injection 20mg vial FDA-approved?
No. The FDA has approved bremelanotide only as Vyleesi 1.75 mg autoinjector for hypoactive sexual desire disorder in premenopausal women. A 20 mg research vial is not FDA-approved for human use, and its safety and purity are not verified.
How does a 20mg vial compare to a PT-141 nasal spray?
A 20 mg vial provides bulk peptide for reconstitution and injection, which allows precise dosing. Nasal sprays deliver bremelanotide through the nasal mucosa and are not FDA-approved. Absorption from nasal sprays can be inconsistent.
How long does PT-141 last after injection?
Bremelanotide has a half-life of about 2.7 hours. Effects are often reported within 1 to 2 hours and may last up to 6 hours. Duration varies by dose, route, and individual factors.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.